The trastuzumab-induced degranulation of NK cells described in our study suggests that the combination of trastuzumab and IL-2-activated KIR-ligand-mismatched NK cells may also trigger a stronger production of cytokines, which could contribute to improved adaptive anti-tumor immunity. The gene discussed is KIR3DL1; the disease is neoplasm.